Attana receives order to perform contract research from an American biotech company
Attana has received an order for contract research from an American biotech company. The contract is related to interaction characterization of therapeutic antibodies using Attana’s cell-based technology. The order value is approximately 300 kSEK and will have a positive effect of the cash flow and results during Q3 2018.
Attana’s application specialists will perform interaction analysis assays. The interaction between a specific target receptor in the cell membrane and a number of potential therapeutic antibodies will be detailed characterized with respect to interactions kinetics and affinity. The results might be used for selecting and optimize the most suitable antibodies for further drug development.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 21.00 CET on July 18, 2018
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact firstname.lastname@example.org.